Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 19/20 | 0.52 |
| ▸ | PRKAB2 | O43741 | 7/20 | 0.51 |
| ▸ | PRKAG1 | P54619 | 7/20 | 0.51 |
| ▸ | PRKAA1 | Q13131 | 7/20 | 0.51 |
| ▸ | PRKAG3 | Q9UGI9 | 7/20 | 0.51 |
| ▸ | PRKAG2 | Q9UGJ0 | 7/20 | 0.51 |
| ▸ | PRKAB1 | Q9Y478 | 7/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4405669 | 0.92 | PRKAA2 (0.49) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL4402628 | 0.89 | PRKAA2 (0.56) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL10112714 | 0.89 | PRKAA2 (0.67) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL648104 | 0.88 | SLC6A5 (0.53) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL647029 | 0.87 | PRKAA2 (0.69) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL650342 | 0.83 | PRKAA2 (0.49) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL649758 | 0.83 | PRKAA2 (0.49) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL649757 | 0.83 | PRKAA2 (0.49) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL10214309 | 0.83 | PRKAA2 (0.70) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL647386 | 0.82 | PRKAA2 (0.75) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119809-B2 | AMPK-activating heterocycloalkyloxy(hetero)aryl carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | PRKAA2 3/4885PRKAB2 6/4885PRKAG1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.